ON-10

ON-10 is a preclinical-stage antibody-drug conjugate (ADC) being developed by OncoOne Research & Development. The asset is part of OncoOne's proprietary 'PreTarg-it' pipeline, which utilizes a pre-targeting technology designed to decouple the antibody's tumor-binding phase from the payload's delivery phase. This approach aims to reduce systemic toxicity and improve the therapeutic index by using bioorthogonal click chemistry to link the payload to the antibody specifically at the tumor site. While OncoOne's primary research focus is on oxidized Macrophage Migration Inhibitory Factor (oxMIF), the specific target and primary disease indications for ON-10 have not been publicly disclosed in detail. The asset is currently in preclinical development for the treatment of solid tumors.